New research indicates that individuals who discontinue popular GLP-1 drugs like Mounjaro or Wegovy tend to recover lost weight far faster than those who end traditional diet and exercise plans.
Published data in a leading medical journal demonstrates that while overweight people frequently drop substantial amounts of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Users using such drugs must be informed of the danger of quick rebound weight gain when the treatment concludes," stated expert Dr. Susan Jebb.
Such speed of regain means a return to starting weight within about a year and a half.
Analyzing Therapies
The research, which looked at 37 of trials involving thousands of participants, contrasted the results of the injectable medications with older methods.
Researchers note that individuals who lose weight through lifestyle changes alone usually see a slower creep back—approximately 0.1 kg a month—post-intervention.
The Reason for the Fast Regain
Nutrition scientists believe the mode of action of the drugs explains the accelerated rebound.
GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Long-term administration of the hormone concentrations far above than normal could lead to the body to produce less of its own natural hormone, and could lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is no longer kept in check, making overeating much more probable."
A Chronic Issue?
The NHS advise the injections for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Professionals say that, due to the likelihood of relapse, the therapy is often ongoing.
This view is reinforced by drug manufacturers, who state that the findings "highlight the persistent character of excess weight," akin to managing conditions like hypertension.
Patient Accounts
Individuals who have discontinued the medication describe a sudden return of hunger.
"It was like a trigger activating and you're instantly ravenous," described a patient.
This difficulty is exacerbated if users have not developed sustainable lifestyle or habit modifications during therapy.
Growing Use
Figures show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is more common among women than males.
- The middle-aged demographic shows the greatest usage rates.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Ultimately, researchers emphasize that while the jabs are potent tools for weight loss, they are not a permanent solution and long-term success likely depends on ongoing behavioural support.
